Lantern Pharma Press Release
Lantern Pharma Chief Scientific Officer Gregory Tobin to Speak at TMED 10: Disruptive Innovation in Healthcare Conference
Dr. Tobin will discuss the role of genomic biomarkers and signatures in the development of Lantern’s portfolio of oncology therapeutics at a leading international conference in translational and personalized medicine.
Press Release – New York, NY – September 4, 2019 – Lantern Pharma, a clinical stage oncology biotech leveraging A.I. and genomics, today announced that its founder and Chief Scientific Officer Gregory Tobin, Ph.D., will speak at TMED 10: Disruptive Innovation in Healthcare, a leading international conference in translational and personalized medicine that brings together leading academic, and clinical researchers and showcasing industry leaders in the life and health science arena.
The conference takes place at the City Hotel, Derry/Londonderry on September 11 and 12, and features a number of sessions featuring leading minds in scientific medicine and technology from around the world. Dr. Tobin’s panel, entitled Identification of Biomarkers for Stratified Clinical Trials, is part of the first day of conference activities, within the Innovations to Improve Clinical Pathways session. View the TMED 10 agenda here.
Dr. Tobin will discuss the role biomarkers and genomic signatures play in the development of stratified precision oncology trials, including LP184. LP184 is Lantern’s next generation DNA-damage repair inhibitor which has shown efficacy in a wide range of solid tumors, including prostate, ovarian, liver and thyroid, that harbor a distinct genomic signature. In addition, Dr. Tobin will provide an overview of the current clinical study being conducted in Northern Ireland in collaboration with The Clinical Translational Research and Innovation Centre (C-TRIC), in Derry, Northern Ireland. C-TRIC is a healthcare and life sciences innovation hub. The clinical study, PRAISE (prostate cancer artificial intelligence study using ex vivo models) is using artificial intelligence to test a cancer drug called LP-184 to predict which types of tumors are most sensitive to LP184. The use of Artificial Intelligence includes data from each of the tumor tests being conducted through drug sensitivity testing and RNA sequencing process, with millions of data points helping to advance the precision development of the drug and the stratification of patients most likely to respond to the therapy.
About Lantern Pharma
Lantern Pharma is a clinical stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. Lantern leverages advances in machine learning, genomics and artificial intelligence by using a proprietary AI platform to discover biomarker signatures that help identify patients more likely to respond to our pipeline of cancer therapeutics. Lantern’s focus is to improve the outcome for patients by leveraging our technology to uncover, rescue and develop abandoned or failed drugs. Lantern seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver cancer therapies to patients as quickly and efficiently as possible.
Lantern’s current therapy product pipeline consists of three drugs, two in clinical stages and one in preclinical, all focusing on cancers that have unique and unmet clinical needs with a clearly defined patient population. Lantern believes that the use of machine learning, genomics and computational methods can help accelerate the development and commercialization of small molecule-based therapies. These drugs can be targeted to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, thereby achieving better outcomes. For more information, please visit the company’s website at www.lanternpharma.com or view company updates on Twitter and LinkedIn.
FischTank Marketing and PR